ALAMEDA, Calif., April 28 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN) today announced that it will release 2005 first quarter
financial results after the close of market on Wednesday, May 11, 2005.
Shortly after the news release is issued, Xenogen's management will host a
conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
What: Xenogen (Nasdaq: XGEN) will release 2005 first quarter results,
followed by a teleconference.
When: Teleconference begins on Wednesday, May 11 at 5:00 p.m. ET
(2:00 p.m. PT).
Who: David Carter, Chief Executive Officer and Chairman; Dr. Pamela
Contag, President; William Albright, Chief Financial Officer.
How: Dial (800) 406-5356 (domestic) or (913) 981-5572 (international) to
listen to the call. A live webcast also will be made available at
http://www.xenogen.com.
A phone replay will be available for 48 hours following the completion of
the call by dialing (888) 203-1112 (domestic) or (719) 457-0820
(international), and entering in reservation code 892-4348. The webcast will
be archived and available on the Xenogen website for 14 days.
About Xenogen Corporation
Xenogen combines systems biology and low-light optical imaging to create
powerful new biophotonic imaging technology that advances the ability of
scientists to explore genes, proteins, pathogens and tumor cells in living
animals in real time, providing predictive data that is designed to
substantially improve the success rate in drug development. Xenogen
incorporates into living animals the bioluminescent gene that makes a firefly
glow and harnesses the resulting light using an ultra-sensitive camera and
sophisticated software. This biophotonic imaging technology creates images and
analyzes the resulting data on cellular activity, gene expression, spread of
disease or the effect of a new drug candidate. Xenogen's biophotonic imaging
technology is used to provide more accurate and previously unavailable data
intended to result in the ability to make more timely and cost-effective
decisions at every step in the drug development process.
NOTE: Xenogen(R) and IVIS(R) are registered trademarks of Xenogen
Corporation.
SOURCE Xenogen Corporation
 back to top
Related links:
http://www.xenogen.com
CONTACT:
William A. Albright, Chief Financial Officer
of Xenogen Corporation, +1-510-291-6104; or investors, Jim Byers
of Financial Dynamics, +1-415-439-4504; or media, Kelly O'Brien
of Manning Selvage & Lee, +1-415-364-3840, both for Xenogen
|
